Adiposs Secures CHF 4 Million to Revolutionize Cancer Imaging
July 2, 2025, 3:33 pm
In the world of medical innovation, every breakthrough can feel like a breath of fresh air. Adiposs, a Swiss startup, has just taken a significant step forward by securing CHF 4 million in a Series A financing round. This funding is not just a number; it represents hope. Hope for cancer patients and hope for a new era in medical imaging.
The investment comes from a diverse group of backers, including Swiss and Taiwanese venture capital firms, European family offices, and high-net-worth individuals. This blend of support showcases a growing interest in innovative healthcare solutions. It’s a collective nod to the potential of Adiposs and its groundbreaking technology.
At the heart of this funding is ImageBAT, a novel contrast agent designed for non-invasive CT imaging of brown fat. This is no ordinary imaging tool. Brown adipose tissue is a critical marker for assessing treatment effectiveness in cancer patients. Unfortunately, current imaging methods struggle to detect this tissue reliably. Adiposs aims to change that narrative.
The company’s mission is clear: to identify non-responding cancer patients early. This is crucial. Early detection can lead to timely interventions, potentially saving lives. Adiposs is stepping into a gap that has long existed in oncology. The promise of ImageBAT is not just in its technology but in its potential to transform patient outcomes.
With the successful closing of this financing round, Adiposs is poised to accelerate its clinical development. The company has already received regulatory approval to initiate the IBT-002 clinical trial. The first subjects were dosed in June 2025, marking a pivotal moment in the company’s journey. Top-line data from this trial is expected in the first quarter of 2026. This timeline is not just a schedule; it’s a countdown to discovery.
The leadership at Adiposs is equally impressive. CEO Andrej Babic leads a team of experts dedicated to pushing the boundaries of what’s possible in cancer care. The recent addition of Peter Lichtlen, MD, and Johnny Chen, MBA, to the Board of Directors strengthens the company’s strategic vision. Lichtlen brings a wealth of experience in biotech and oncology, having achieved multiple successful exits. Chen’s background in venture capital and private equity adds a layer of financial acumen that will be invaluable as Adiposs navigates its growth.
Adiposs is not just another startup; it’s a beacon of hope in the oncology landscape. The company’s proprietary technology leverages standard-of-care oncology CT scans, which are already widely available in hospitals. This positions Adiposs at the forefront of scalable innovation. It’s a smart move, allowing for broader adoption without the need for specialized equipment.
The journey of Adiposs is also a testament to the entrepreneurial spirit thriving in Switzerland. The company has garnered recognition through initiatives like Venture Kick and has participated in Venture Leaders. Being ranked among the TOP 100 Swiss startups is no small feat. It reflects the company’s potential and the confidence investors have in its vision.
The need for innovation in cancer care is urgent. Traditional imaging methods often fall short, leaving gaps in diagnosis and treatment planning. Adiposs aims to fill these gaps with its cutting-edge technology. The ability to visualize brown fat non-invasively could change the way oncologists approach treatment. It’s like turning on a light in a dark room, illuminating paths that were previously obscured.
As the healthcare landscape evolves, the role of technology becomes increasingly vital. Startups like Adiposs are at the forefront of this evolution. They are not just creating products; they are crafting solutions that address real-world problems. The impact of their work can ripple through the healthcare system, improving outcomes for patients and reducing costs for providers.
In conclusion, Adiposs’s recent funding round is more than just a financial milestone. It’s a signal of progress in the fight against cancer. With ImageBAT, the company is not only advancing technology but also enhancing the quality of care for patients. The journey ahead is filled with promise, and the upcoming clinical trial results could pave the way for a new standard in cancer imaging. As we await these results, one thing is clear: Adiposs is a name to watch in the world of medical innovation. The future of cancer care may very well hinge on their success.
The investment comes from a diverse group of backers, including Swiss and Taiwanese venture capital firms, European family offices, and high-net-worth individuals. This blend of support showcases a growing interest in innovative healthcare solutions. It’s a collective nod to the potential of Adiposs and its groundbreaking technology.
At the heart of this funding is ImageBAT, a novel contrast agent designed for non-invasive CT imaging of brown fat. This is no ordinary imaging tool. Brown adipose tissue is a critical marker for assessing treatment effectiveness in cancer patients. Unfortunately, current imaging methods struggle to detect this tissue reliably. Adiposs aims to change that narrative.
The company’s mission is clear: to identify non-responding cancer patients early. This is crucial. Early detection can lead to timely interventions, potentially saving lives. Adiposs is stepping into a gap that has long existed in oncology. The promise of ImageBAT is not just in its technology but in its potential to transform patient outcomes.
With the successful closing of this financing round, Adiposs is poised to accelerate its clinical development. The company has already received regulatory approval to initiate the IBT-002 clinical trial. The first subjects were dosed in June 2025, marking a pivotal moment in the company’s journey. Top-line data from this trial is expected in the first quarter of 2026. This timeline is not just a schedule; it’s a countdown to discovery.
The leadership at Adiposs is equally impressive. CEO Andrej Babic leads a team of experts dedicated to pushing the boundaries of what’s possible in cancer care. The recent addition of Peter Lichtlen, MD, and Johnny Chen, MBA, to the Board of Directors strengthens the company’s strategic vision. Lichtlen brings a wealth of experience in biotech and oncology, having achieved multiple successful exits. Chen’s background in venture capital and private equity adds a layer of financial acumen that will be invaluable as Adiposs navigates its growth.
Adiposs is not just another startup; it’s a beacon of hope in the oncology landscape. The company’s proprietary technology leverages standard-of-care oncology CT scans, which are already widely available in hospitals. This positions Adiposs at the forefront of scalable innovation. It’s a smart move, allowing for broader adoption without the need for specialized equipment.
The journey of Adiposs is also a testament to the entrepreneurial spirit thriving in Switzerland. The company has garnered recognition through initiatives like Venture Kick and has participated in Venture Leaders. Being ranked among the TOP 100 Swiss startups is no small feat. It reflects the company’s potential and the confidence investors have in its vision.
The need for innovation in cancer care is urgent. Traditional imaging methods often fall short, leaving gaps in diagnosis and treatment planning. Adiposs aims to fill these gaps with its cutting-edge technology. The ability to visualize brown fat non-invasively could change the way oncologists approach treatment. It’s like turning on a light in a dark room, illuminating paths that were previously obscured.
As the healthcare landscape evolves, the role of technology becomes increasingly vital. Startups like Adiposs are at the forefront of this evolution. They are not just creating products; they are crafting solutions that address real-world problems. The impact of their work can ripple through the healthcare system, improving outcomes for patients and reducing costs for providers.
In conclusion, Adiposs’s recent funding round is more than just a financial milestone. It’s a signal of progress in the fight against cancer. With ImageBAT, the company is not only advancing technology but also enhancing the quality of care for patients. The journey ahead is filled with promise, and the upcoming clinical trial results could pave the way for a new standard in cancer imaging. As we await these results, one thing is clear: Adiposs is a name to watch in the world of medical innovation. The future of cancer care may very well hinge on their success.